Similar Papers

Paper Title
Journal
Date
Author
Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: ASystematic Review.
Yulin Liang ... Vincent Doré
Journal of Alzheimer's Disease Reports | VOL. 8
Yulin Liang, et. al.Yulin Liang ... Vincent Doré
07 May 2024
Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
...
Diabetes care | VOL. 46
, et. al. ...
25 Jun 2023
Comparing Clinical Outcomes and Costs for Different Treatment Intensification Approaches in Patients with Type 2 Diabetes Uncontrolled On Basal Insulin: Adding Glucagon-Like Peptide 1 Receptor Agonists Versus Adding Rapid-Acting Insulin or Increasing Basal Insulin Dose
Philip Levin ... Bong-Chul Chu
Endocrine Practice | VOL. 23
Philip Levin, et. al.Philip Levin ... Bong-Chul Chu
01 Nov 2017
Hba1C Control And Cost-Effectiveness in Patients With Type 2 Diabetes Mellitus Initiated On Canagliflozin or A Glucagon-Like Peptide 1 Receptor Agonist in A Real-World Setting
Carol H Wysham ... Patrick Lefebvre
Endocrine Practice | VOL. 24
Carol H Wysham, et. al.Carol H Wysham ... Patrick Lefebvre
01 Mar 2018
View more papers

More From: International Journal of Endocrinology and Diabetes

Paper Title
Journal
Date
Author
-
-
International Journal of Endocrinology and Diabetes | VOL. 7
--
25 Dec 2024
American Diabetes Association Standards of Care 2025: New Recommendations for Diabetes Self-Management Education and Support(DSMES)
-
International Journal of Endocrinology and Diabetes | VOL. 7
--
25 Dec 2024
Consequences of Iatrogenic Insulin Resistance and How to Mitigate These Risks
-
International Journal of Endocrinology and Diabetes | VOL. -
--
29 Nov 2024
-
-
International Journal of Endocrinology and Diabetes | VOL. -
--
29 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.